The combination of 9 different CSF biomarkers [36] [namely soluble amyloid precursor protein a (sAPPa), soluble amyloid precursor protein b (sAPPb), Mammalian Chitinase-Like Protein-40 (YKL), Monocyte Chemoattractant Protein-1 (MCP-1), NfL, P-Tau, T-Tau, a-synuclein (a-syn), and Ab42] differentiates with a good accuracy 14 CBS patients from 31 PD patients (AUC 0.98, 95%CI 0.97–0.99), from 26 AD and 16 FTD patients (AUC 0.93, 95%CI 0.85–0.99). This evidence concerns the gene NEFL and Parkinson disease.